Roivant Sciences and Plexcera Therapeutics have today launched a new biotech company with a singular focus on the ultrarare condition known as Farber disease,…

New York preclinical cancer biotech Sapience Therapeutics has managed to gain a $22.5 million pot of cash in its first funding round as it looks to progress…

Flagship Ventures hopes to create a new immune-microbiome company that will have a candidate in the clinic next year--through the combination of a pair of its…

French NASH and fibrosis disease biotech Inventiva is looking to build on its Big Pharma interest by filing for an IPO on the Euronext.

Christine Placet has rounded up money for an ophthalmic gene therapy company, her first venture since leading Trophos to a $470 million takeover by Roche.

It’s an awkward age, to be 15. But that’s exactly where we are with the Fierce 15 this year.

Only 12 IPOs made it out last quarter from U.S. venture-backed companies. Of those, 9 were for biotech companies.

Aprecia Pharmaceuticals has secured $30 million in debt to launch the first 3-D printed pharmaceutical product and bring forward more 3-D printed fast-melt…